The pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases. The researchers developed an antibody that improves glucose regulation and reduces fatty liver in obese mice by targeting a hormone in adipose (fat) tissue called aP2 (also known as FABP4).
The study is published in the journal Science Translational Medicine.
"The importance of this study is two-fold: first, demonstrating the importance of aP2 as a critical hormone in abnormal glucose metabolism, and secondly, showing that aP2 can be effectively targeted to treat diabetes and potentially other immunometabolic diseases," said the author.
The increase in adipose tissue characteristic of obesity has long been linked to increased risk for metabolic diseases such as type 2 diabetes and cardiovascular disease. Recently, it has become clear that the tissue itself plays an active role in metabolic disease, in part by releasing hormones which act in distant sites such as the liver, muscle, and brain that affect systemic metabolism.
The lab previously identified the protein aP2 as a critical hormone mediating communication between adipose tissue and liver. Since aP2 levels are significantly increased in humans with obesity, diabetes, and atherosclerosis, and mutations that reduce aP2 result in significantly reduced risk of diabetes, dyslipidemia, and heart disease, strategies to modify aP2 function carry promise as new lines of therapeutic entities against these common and debilitating chronic diseases.
In the new study, researchers describe the development and evaluation of novel monoclonal antibodies targeting aP2. The team found that one of these antibodies effectively improved glucose regulation in two independent models of obesity. Additionally, beneficial reductions in liver fat were observed.
These monoclonal antibodies have the potential to be transformative first-in-class therapeutics to fight obesity-related metabolic and immunometabolic disease, say the authors. This work is still at the preclinical stage and will require extensive evaluation for safety and effectiveness before being considered for use in humans.
http://www.hsph.harvard.edu/news/press-releases/targeting-fat-tissue-hormone-may-lead-to-type-2-diabetes-treatment/
Edited
Latest News
Connecting genetic risk for…
By newseditor
Posted 30 May
Tumor infiltration of immun…
By newseditor
Posted 28 May
New light-controlled 'off s…
By newseditor
Posted 28 May
Gene function during embryo…
By newseditor
Posted 28 May
Formation of 3D blood vesse…
By newseditor
Posted 27 May
Other Top Stories
Vessel co-option mediates resistance to anti-angiogenic therapy in…
Read more
A novel non-invasive imaging probe for fast and sensitive detection…
Read more
Anti-cancer effects found in natural compound derived from onions
Read more
Role of prolactin in triple negative breast cancer
Read more
Fat in feces points to early presence of colorectal cancer
Read more
Protocols
Accessible high-speed image…
By newseditor
Posted 30 May
SEMORE: SEgmentation and MO…
By newseditor
Posted 26 May
Spatially resolved lipidomi…
By newseditor
Posted 24 May
Efficient expansion and CRI…
By newseditor
Posted 21 May
Massively parallel in vivo…
By newseditor
Posted 20 May
Publications
I Am Curious About Cannabis…
By newseditor
Posted 30 May
Advanced microbiome therape…
By newseditor
Posted 29 May
Hippocampal astrocytes indu…
By newseditor
Posted 29 May
TNIK's emerging role in can…
By newseditor
Posted 29 May
Diabetes drugs activate neu…
By newseditor
Posted 29 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar